文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

高流量鼻导管氧疗在COVID-19肺炎中的有效性:一项回顾性队列研究

The Effectiveness of High-Flow Nasal Cannula in Coronavirus Disease 2019 Pneumonia: A Retrospective Cohort Study.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论重症COVID-19肺炎中,HFNC整体未显著降低死亡风险,但排除入院6小时内插管者后死亡风险显著降低(aHR 0.67)。

该回顾性队列研究纳入约翰斯·霍普金斯五家医院收治的实验室确诊COVID-19患者,采用时间依赖倾向评分匹配比较HFNC与对照。主要分析中HFNC与死亡风险无显著关联(aHR 0.79,95%CI 0.57-1.09),但排除入院6小时内插管者后死亡风险显著降低(aHR 0.67,95%CI 0.45-0.99)。HFNC与更长中位出院时间相关(10.6天 vs 7.8天)。呼吸频率-氧合指数对进展至有创机械通气或死亡的预测能力差。

要点

  • 在重症COVID-19肺炎未筛选患者中,HFNC与死亡风险无显著关联(aHR 0.79;95%CI 0.57-1.09)。
  • 排除入院6小时内插管者后,HFNC与死亡风险显著降低相关(aHR 0.67;95%CI 0.45-0.99)。
  • HFNC组中位出院时间更长:10.6天(IQR 7.1-15.8)vs 对照组7.8天(IQR 4.9-12.1)。
  • 呼吸频率-氧合指数对预测进展至有创机械通气或死亡的表现差。

适用人群与场景

  • 约翰斯·霍普金斯卫生系统五家医院收治的实验室确诊COVID-19患者,所有入院患者均符合纳入条件。
  • 研究场景为住院治疗,未明确限定急诊、ICU或院前;病情阶段为重症COVID-19肺炎。

诊断标准与关键阈值

  • 诊断标准:实验室确诊COVID-19。
  • 呼吸频率-氧合指数用于预测进展至有创机械通气,但原文未给出具体界值或阈值,且报告其预测能力差。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。
  • HFNC启动时机、参数设置及疗程原文未提及。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征及相应处理。

研究设计与关键结果

  • 研究类型:回顾性队列研究,采用时间依赖倾向评分匹配,样本量与中心数原文未明确报告(五家医院)。
  • 人群:实验室确诊COVID-19入院患者;干预:高流量鼻导管氧疗;对照:匹配的未使用HFNC患者。
  • 主要终点:HFNC与更长中位出院时间相关:10.6天(IQR 7.1-15.8)vs 7.8天(IQR 4.9-12.1)。
  • 主要分析:HFNC与死亡风险无显著关联(aHR 0.79;95%CI 0.57-1.09)。
  • 二次分析排除入院6小时内插管者后,HFNC与死亡风险显著降低相关(aHR 0.67;95%CI 0.45-0.99)。
  • 呼吸频率-氧合指数对预测有创机械通气或死亡表现差。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 证据等级或推荐强度:原文未提及。
  • 局限:回顾性设计、观察性研究可能存在残余混杂;原文未报告样本量、单中心或多中心的具体中心数(仅提及五家医院);时间依赖倾向评分匹配方法本身可能引入选择偏倚;呼吸频率-氧合指数预测能力差提示其不适用于决策。

对床旁实践的改变

  • 在重症COVID-19肺炎未筛选患者中,HFNC不应被视为能显著降低死亡风险的确定性治疗。
  • 对于入院6小时内未插管的患者,HFNC可能与死亡风险降低相关,但该结果来自回顾性二次分析,需前瞻性验证。
  • 呼吸频率-氧合指数不宜用于预测HFNC患者进展至有创机械通气或死亡的风险。
  • 使用HFNC可能与更长出院时间相关,资源分配时需考虑。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: High-flow nasal cannula is widely used in acute hypoxemic respiratory failure due to coronavirus disease 2019, yet data regarding its effectiveness is lacking. More evidence is needed to guide patient selection, timing of high-flow nasal cannula initiation, and resource allocation. We aimed to assess time to discharge and time to death in severe coronavirus disease 2019 in patients treated with high-flow nasal cannula compared with matched controls. We also evaluated the ability of the respiratory rate-oxygenation ratio to predict progression to invasive mechanical ventilation.

DESIGN: Time-dependent propensity score matching was used to create pairs of individuals who were then analyzed in a Cox proportional-hazards regression model to estimate high-flow nasal cannula's effect on time to discharge and time to death. A secondary analysis excluded high-flow nasal cannula patients intubated within 6 hours of admission. A Cox proportional-hazards regression model was used to assess risk of invasive mechanical ventilation among high-flow nasal cannula patients stratified by respiratory rate-oxygenation.

SETTING: The five hospitals of the Johns Hopkins Health System.

PATIENTS: All patients who were admitted with a laboratory-confirmed diagnosis of coronavirus disease 2019 were eligible for inclusion.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: High-flow nasal cannula was associated with longer median time to discharge: 10.6 days (interquartile range, 7.1-15.8 d) versus 7.8 days (interquartile range, 4.9-12.1 d). Respiratory rate-oxygenation index performed poorly in predicting ventilation or death. In the primary analysis, there was no significant association between high-flow nasal cannula and hazard of death (adjusted hazard ratio, 0.79; 95% CI, 0.57-1.09). Excluding patients intubated within 6 hours of admission, high-flow nasal cannula was associated with reduced hazard of death (adjusted hazard ratio, 0.67; 95% CI, 0.45-0.99).

CONCLUSIONS: Among unselected patients with severe coronavirus disease 2019 pneumonia, high-flow nasal cannula was not associated with a statistically significant reduction in hazard of death. However, in patients not mechanically ventilated within 6 hours of admission, high-flow nasal cannula was associated with a significantly reduced hazard of death.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Burnim MS, Wang K, Checkley W, et al. The Effectiveness of High-Flow Nasal Cannula in Coronavirus Disease 2019 Pneumonia: A Retrospective Cohort Study. Crit Care Med. 2022. PMID: 34637419. doi:10.1097/CCM.0000000000005309

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。